Literature DB >> 24111544

Fluctuations in pathogenic CD4+ T-cell subsets in a murine sclerodermatous model of chronic graft-versus-host disease.

Ji-Young Lim1, Byung-Sik Cho, Chang-Ki Min, Gyeongsin Park, Yoo-Jin Kim, Nak-Gyun Chung, Dae-Chul Jeong, Woo-Sung Min.   

Abstract

To determine the roles of CD4+ T-cell (Th) subsets, including Th17 cells, in the development of chronic graft-versus-host disease (cGVHD), we used a Th-dependent cGVHD model comprising B10.D2 donor and BALB/c recipient mice. The clinical GVHD score increased beginning at day +14, peaked at day +42, and remained elevated until day +70. In the skin, increased dermal thickness was apparent at day +14, and maintained with few changes until day +70. In contrast, the liver had peak pathologic scores at day +28, and the tissue damage began to improve at day +56. To determine possible associations between improvement of liver pathology and changes in Th subsets, we analyzed Th subsets using flow cytometry. Th1 frequencies in the livers were greater than other Th subsets throughout the disease course, but the frequencies decreased over time. Notably, Th17 cells were rarely detected during earlier periods, but emerged at day +56, which correlated with the improved hepatic inflammation. In contrast, other Th subsets (Th2 and regulatory T cells) did not change significantly during the disease course. These results indicate the association of attenuation on cGVHD with a later emergence of Th17 cells and concomitant decrease of Th1 cells.

Entities:  

Mesh:

Year:  2013        PMID: 24111544     DOI: 10.3109/08820139.2013.843191

Source DB:  PubMed          Journal:  Immunol Invest        ISSN: 0882-0139            Impact factor:   3.657


  4 in total

1.  Ibrutinib treatment ameliorates murine chronic graft-versus-host disease.

Authors:  Jason A Dubovsky; Ryan Flynn; Jing Du; Bonnie K Harrington; Yiming Zhong; Benjamin Kaffenberger; Carrie Yang; William H Towns; Amy Lehman; Amy J Johnson; Natarajan Muthusamy; Steven M Devine; Samantha Jaglowski; Jonathan S Serody; William J Murphy; David H Munn; Leo Luznik; Geoffrey R Hill; Henry K Wong; Kelli K P MacDonald; Ivan Maillard; John Koreth; Laurence Elias; Corey Cutler; Robert J Soiffer; Joseph H Antin; Jerome Ritz; Angela Panoskaltsis-Mortari; John C Byrd; Bruce R Blazar
Journal:  J Clin Invest       Date:  2014-10-01       Impact factor: 14.808

2.  Inducible T-Cell Co-Stimulator Impacts Chronic Graft-Versus-Host Disease by Regulating Both Pathogenic and Regulatory T Cells.

Authors:  Mengmeng Zhang; Yongxia Wu; David Bastian; Supinya Iamsawat; Jinsam Chang; Anusara Daenthanasanmak; Hung D Nguyen; Steven Schutt; Min Dai; Fangping Chen; Woong-Kyung Suh; Xue-Zhong Yu
Journal:  Front Immunol       Date:  2018-06-22       Impact factor: 7.561

3.  CCL1 blockade alleviates human mesenchymal stem cell (hMSC)-induced pulmonary fibrosis in a murine sclerodermatous graft-versus-host disease (Scl-GVHD) model.

Authors:  Ji-Young Lim; Da-Bin Ryu; Tae Woo Kim; Sung-Eun Lee; Gyeongsin Park; Hyoung Kyu Yoon; Chang-Ki Min
Journal:  Stem Cell Res Ther       Date:  2020-06-26       Impact factor: 6.832

4.  Differential Effect of MyD88 Signal in Donor T Cells on Graft-versus-Leukemia Effect and Graft-versus-Host Disease after Experimental Allogeneic Stem Cell Transplantation.

Authors:  Ji-Young Lim; Da-Bin Ryu; Sung-Eun Lee; Gyeongsin Park; Eun Young Choi; Chang-Ki Min
Journal:  Mol Cells       Date:  2015-11-10       Impact factor: 5.034

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.